WallStSmart

CBRE Group Inc Class A (CBRE)vsEUDA Health Holdings Limited (EUDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CBRE Group Inc Class A generates 785707% more annual revenue ($40.55B vs $5.16M). EUDA leads profitability with a 5.2% profit margin vs 2.9%. EUDA trades at a lower P/E of 0.9x. CBRE earns a higher WallStSmart Score of 56/100 (C).

CBRE

Buy

56

out of 100

Grade: C

Growth: 4.7Profit: 4.5Value: 7.3Quality: 5.8
Piotroski: 4/9Altman Z: 2.85

EUDA

Hold

36

out of 100

Grade: F

Growth: 5.3Profit: 3.0Value: 8.3Quality: 4.5
Piotroski: 2/9Altman Z: -74.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CBRESignificantly Overvalued (-471.0%)

Margin of Safety

-471.0%

Fair Value

$26.18

Current Price

$134.75

$108.57 premium

UndervaluedFair: $26.18Overvalued
EUDAUndervalued (+68.0%)

Margin of Safety

+68.0%

Fair Value

$2.72

Current Price

$11.47

$8.75 discount

UndervaluedFair: $2.72Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CBRE2 strengths · Avg: 8.0/10
PEG RatioValuation
0.798/10

Growing faster than its price suggests

Free Cash FlowQuality
$1.08B8/10

Generating 1.1B in free cash flow

EUDA3 strengths · Avg: 10.0/10
P/E RatioValuation
0.9x10/10

Attractively priced relative to earnings

Revenue GrowthGrowth
60.2%10/10

Revenue surging 60.2% year-over-year

Debt/EquityHealth
-0.6210/10

Conservative balance sheet, low leverage

Areas to Watch

CBRE4 concerns · Avg: 3.0/10
P/E RatioValuation
34.5x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
2.9%3/10

2.9% margin — thin

Operating MarginProfitability
0.1%3/10

Operating margin of 0.1%

EPS GrowthGrowth
-12.1%2/10

Earnings declined 12.1%

EUDA4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$692,0703/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
5.2%3/10

5.2% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : CBRE

The strongest argument for CBRE centers on PEG Ratio, Free Cash Flow. Revenue growth of 11.8% demonstrates continued momentum. PEG of 0.79 suggests the stock is reasonably priced for its growth.

Bull Case : EUDA

The strongest argument for EUDA centers on P/E Ratio, Revenue Growth, Debt/Equity. Revenue growth of 60.2% demonstrates continued momentum.

Bear Case : CBRE

The primary concerns for CBRE are P/E Ratio, Profit Margin, Operating Margin. Thin 2.9% margins leave little buffer for downturns.

Bear Case : EUDA

The primary concerns for EUDA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

CBRE profiles as a value stock while EUDA is a hypergrowth play — different risk/reward profiles.

CBRE carries more volatility with a beta of 1.34 — expect wider price swings.

EUDA is growing revenue faster at 60.2% — sustainability is the question.

CBRE generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

CBRE scores higher overall (56/100 vs 36/100) and 11.8% revenue growth. EUDA offers better value entry with a 68.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CBRE Group Inc Class A

REAL ESTATE · REAL ESTATE SERVICES · USA

CBRE Group, Inc. is an American commercial real estate services and investment firm. The abbreviation CBRE stands for Coldwell Banker Richard Ellis. It is the largest commercial real estate services company in the world.

EUDA Health Holdings Limited

REAL ESTATE · REAL ESTATE SERVICES · USA

EUDA Health Holdings Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative therapies for rare diseases and unmet medical needs. Utilizing advanced technologies and a dynamic pipeline, the company aims to tackle critical challenges in supportive care and immune modulation. With a strong emphasis on research and development, EUDA is well-positioned to lead healthcare innovation, committed to improving patient outcomes and expanding access to vital medical therapies through its promising clinical programs.

Visit Website →

Want to dig deeper into these stocks?